Business / Finance

RSS

Generative AI approach unlocks path to accelerated antibody drug creation for novel therapeutic targets

A recent study used generative AI models to develop de novo design antibodies against three distinct targets in a zero-shot fashion.

11 Jan 2023

Sustainable Laboratory Product of the Year - CellDrop Automated Cell Counter

The DeNovix CellDrop™ Automated Cell Counter has been awarded Sustainable Laboratory Product of the Year in the SelectScience® Scientists’ Choice Awards®.

From DeNovix Inc. 11 Jan 2023

Evosep receives strategic investment from Novo Holding A/S to accelerate its effort on clinical proteomics

Evosep today announced that Novo Holdings A/S has become a minority shareholder in Evosep Aps with a US$ 40m investment to further Evosep’s technology and application portfolio for clinical proteomics.

From Evosep 10 Jan 2023

Complete Genomics Launches Full Sequencing Platforms at Biotech Showcase™ 2023

...

From MGI 10 Jan 2023

Vector BioPharma and iBET collaborate to develop high-throughput analytical methods and scalable processes for gene delivery

Collaboration set to develop and implement high-throughput analytical methods in support of Vector BioPharma’s CMC (chemistry, manufacturing and controls) development.

From Vector BioPharma 10 Jan 2023

Astrea Bioseparations acquires Delta Precision Ltd, a leading manufacturer of chromatography columns for biomanufacturing

Astrea Bioseparations, a leading provider of high-quality bioseparation and purification technologies, announced today the acquisition of Delta Precision Ltd., a premier manufacturer of advanced chromatography columns for the biotechnology and pharmaceutical industries.

10 Jan 2023

Ubiquigent appoints Dr Xavier Jacq to Scientific Advisory Board

Ubiquigent Limited (Ubiquigent), a drug discovery and development company harnessing novel deubiquitinase (DUB) modulators as new therapeutics for areas of high unmet medical need, today announced the appointment of Dr Xavier Jacq to its Scientific Advisory Board (SAB).

10 Jan 2023

Cerba Research is officially a member of Hong Kong Bio-Med Innotech Association (HKBMIA)

Cerba Research announces membership of HKBMIA to act as an advisor on speciality testing and routine clinical trials testing to advance research and health while supporting Asia pacific healthcare companies develop new therapeutics.

From Cerba Research 6 Jan 2023

PhoreMost and Boehringer Ingelheim enter multi-project drug discovery collaboration

PhoreMost Limited, the UK-based biopharmaceutical company dedicated to drugging ‘undruggable’ disease targets, today announced it has entered into a multi-project drug discovery collaboration with Boehringer Ingelheim, one of the world-leading pharmaceutical companies developing innovative therapies for diseases with unsatisfactory treatments.

5 Jan 2023

RQM+ Launches Clinical Trial Services

RQM+ today announced the launch of its clinical trial services division to complete its full complement of MedTech contract research organization (CRO) services.

From RQM+ 4 Jan 2023

Berkeley Lights to Acquire IsoPlexis, Creating a Premier Functional Cell Biology Company

Berkeley Lights (Nasdaq: BLI) and IsoPlexis (Nasdaq: ISO) today announced a definitive agreement under which Berkeley Lights will acquire IsoPlexis in an all-stock transaction valued at $57.8 million.

From Bruker Cellular Analysis 3 Jan 2023

Fujifilm announces asset purchase agreement with Inspirata, Inc. to acquire the company’s digital pathology business

FUJIFILM Corporation (President and CEO, Representative Director: Teiichi Goto) today announced the company has entered into an asset purchase agreement to acquire the global digital pathology business of Tampa, Florida-based Inspirata, Inc. Upon completion of this agreement, Inspirata's Dynamyx® digital pathology technology, employees and customers will become part of Fujifilm.

From FUJIFILM Corporation 20 Dec 2022

CN Bio appoints Dr Paul Brooks as Chief Executive Officer

CN Bio, a leading Organ-on-a-chip Company (OOC) that designs and manufactures single-and multi-organ microphysiological systems (MPS), today announced the appointment of Dr Paul Brooks, formerly the Company’s Chief Business Officer, to the position of CEO with immediate effect. Former CEO, Dr David Hughes, will continue to work with the company in a consultative role within the Company’s Scientific Advisory Board.

From CN-Bio 19 Dec 2022

Global Access Diagnostics joins consortium to co-develop on-farm rapid test for calf pneumonia, RaDiCal

Global Access Diagnostics (GADx) today announced the development of RaDiCal, a one-step molecular lateral flow test to enable rapid diagnosis of pneumonia, one of the most significant diseases affecting calves

From Global Access Diagnostics 16 Dec 2022

PhoreMost and ThinkCyte collaborate to advance AI based drug discovery

PhoreMost Ltd. and ThinkCyte K.K today announced a strategic research partnership aimed at advancing modern phenotypic drug screening using artificial intelligence (AI).

From PhoreMost 16 Dec 2022

INTEGRA Biosciences furthers scientific education with festive donation

INTEGRA Biosciences is proud to be supporting the Smithsonian Science Education Center (SSEC) with a $20,000 donation this festive season.

From INTEGRA Biosciences 16 Dec 2022

Sphere Fluidics appoints Richard Hammond as Chief Technical Officer

Sphere Fluidics, a company developing single cell analysis systems underpinned by its patented picodroplet technology, announced today that it has appointed Richard Hammond as Chief Technical Officer.

From Sphere Fluidics 16 Dec 2022

Metrion Biosciences and The KCNC1 Foundation Collaborate on New Ion Channel Modulators

...

From Metrion Biosciences Limited 7 Dec 2022

Envomed appoints Hagai Yehidi as new CEO

Envomed, the brand behind the Envomed80 on-site medical waste treatment solution, has appointed Hagai Yehidi as its new CEO.

From Envomed 29 Nov 2022

Sartorius BIA Separations and Exopharm Sign Joint Research Agreement to Develop Integrated Technology

Sartorius BIA Separations (BIA), a leading bio-chromatography company, now part of the international life science group Sartorius, and Exopharm Ltd. (ASX:EX1), a company at the forefront of transformative medicines using exosomes, or extracellular vesicles (EVs), today announced they had entered into a formal collaboration.

From Sartorius 23 Nov 2022